Only three medications are approved by the Food and Drug Administration (FDA) for the treatment of alcohol dependence, namely disulfiram, naltrexone and acamprosate. However, the findings for efficacy of disulfiram are minimal and treatment effects for naltrexone and acamprosate are modest. There exists a substantial need for discovering ways to provide more effective treatments. Accordingly, identifying new potential neuropharmacological targets in the treatment of alcohol dependence represents a high priority of National Institute on Alcohol Abuse and Alcoholism (NIAAA). Ghrelin is a 28-amino acid peptide acting as the endogenous ligand for the growth hormone secretagogue receptor (GHS-R). Ghrelin was first isolated from the stomach, but a central hypothalamic production of ghrelin has also been demonstrated. Ghrelin plays a key role in the regulation of appetite. Consistent with the common neurobiological substrates for control of food and alcohol consumption, preclinical investigations suggest that ghrelin plays a role in the neurobiology of alcohol dependence, thus representing a new potential neuropharmacology target. In keeping with the preclinical studies, our and other groups'human investigations showed how alcohol consumption affects blood ghrelin levels and that blood ghrelin levels significantly and positively correlate with craving measurements in alcohol-dependent individuals. The effects of exogenous ghrelin injected i.v. in alcohol-dependent individuals, however, have never been investigated. The current project proposes a randomized double-blind placebo-controlled 3-group between- subject laboratory study aimed at investigating the effects of exogenous ghrelin i.v. on non-treatment seeking alcohol-dependent subjects in terms of urges to drink, attention to cues and related psychophysiological measures. This Exploratory/Developmental project has the goals to: i) conduct an alcohol laboratory study testing the role of ghrelin i.v., therefore demonstrating the feasibility of such a study and the safety of ghrelin i.v. when administered to alcohol-dependent individuals;and ii) explore the effects of ghrelin i.v. on alcohol craving assessed under controlled conditions, such as a cue-reactivity experiment. This study will address whether alcohol craving is affected when ghrelin levels are modified acutely via a ghrelin i.v. injection. Given the crucial need to expand our understanding of the underlying neurobiology of alcoholism, this study potentially will lead to identify new targets for the development of pharmacological treatments that may improve interventions for alcohol dependent individuals.

Public Health Relevance

Public Health Relevance Alcohol use disorders account for 100,000 excess deaths per year and considerable mortality and morbidity. There exists a substantial need for discovering new, more effective treatments for alcohol use disorders. Research has identified the ghrelin system as a mediator of alcohol craving. Better characterizing the role of ghrelin in the biobehavioral effects of alcohol may lead to more effective pharmacological treatments for alcohol use disorders.

Agency
National Institute of Health (NIH)
Institute
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AA019709-01
Application #
7962839
Study Section
Health Services Research Review Subcommittee (AA)
Program Officer
Fertig, Joanne
Project Start
2010-09-10
Project End
2012-08-31
Budget Start
2010-09-10
Budget End
2011-08-31
Support Year
1
Fiscal Year
2010
Total Cost
$202,500
Indirect Cost
Name
Brown University
Department
Public Health & Prev Medicine
Type
Schools of Public Health
DUNS #
001785542
City
Providence
State
RI
Country
United States
Zip Code
02912
Haass-Koffler, Carolina L; Giovenco, Danielle E; Lee, Mary R et al. (2016) Serum Insulin Levels Are Reduced by Intravenous Ghrelin Administration but Do Not Correlate with Alcohol Craving in Alcohol-Dependent Individuals. Int J Neuropsychopharmacol :
Haass-Koffler, C L; Aoun, E G; Swift, R M et al. (2015) Leptin levels are reduced by intravenous ghrelin administration and correlated with cue-induced alcohol craving. Transl Psychiatry 5:e646
Haass-Koffler, Carolina L; Leggio, Lorenzo; Kenna, George A (2014) Pharmacological approaches to reducing craving in patients with alcohol use disorders. CNS Drugs 28:343-60
Vuittonet, Cynthia L; Halse, Michael; Leggio, Lorenzo et al. (2014) Pharmacotherapy for alcoholic patients with alcoholic liver disease. Am J Health Syst Pharm 71:1265-76
Leggio, Lorenzo; Zywiak, William H; Fricchione, Samuel R et al. (2014) Intravenous ghrelin administration increases alcohol craving in alcohol-dependent heavy drinkers: a preliminary investigation. Biol Psychiatry 76:734-41
Kenna, George A; Swift, Robert M; Hillemacher, Thomas et al. (2012) The relationship of appetitive, reproductive and posterior pituitary hormones to alcoholism and craving in humans. Neuropsychol Rev 22:211-28
Leggio, L; Ferrulli, A; Zambon, A et al. (2012) Baclofen promotes alcohol abstinence in alcohol dependent cirrhotic patients with hepatitis C virus (HCV) infection. Addict Behav 37:561-4
Leggio, Lorenzo; Ferrulli, Anna; Cardone, Silvia et al. (2012) Ghrelin system in alcohol-dependent subjects: role of plasma ghrelin levels in alcohol drinking and craving. Addict Biol 17:452-64